Although biological markers including PD-L1 expression levels, tumor mutational burden (TMB), hematological biological markers, and composite biological markers are presently under scrutiny as potential indicators for assessing the reaction to ICIs in NSCLC patients, none have gained widespread and accurate clinical utilization. This evidence concerns the gene CD274 and non-small cell lung carcinoma.